Abstract
The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) in the progress of the neurodegenerative disorder Alzheimer´s disease (AD) and it is now widely accepted that Aβ is related to the pathogenesis of AD. For example, studies have shown that Aβ is neurotoxic and that the neurotoxicity of Aβ is related to its aggregation state. The concentration of the 42 amino acid form of Aβ (Aβ1-42) is reduced in the cerebrospinal fluid (CSF) from AD patients, which is believed to reflect the AD pathology with plaques in the brain acting as sinks. Less well investigated, however, is the ability of other Aβ isoforms to distinguish AD patients from controls and to identify treatment effects in clinical trials. Recently, novel C-truncated forms of Aβ (Aβ1-14, Aβ1-15, and Aβ1-16) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by β- followed by α-secretase. It has been shown that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged. Here, we review the many aspects of Aβ and its isoforms with special focus on their potential role as diagnostic and theragnostic markers.
Keywords: Alzheimer's disease, Amyloid, APP, biomarker, theragnostic marker, Abeta-degrading enzymes, Down's syndrome, mass spectrometry, amino acid, Western blot, Subventricular Zone (SVZ) Derived Oligodendrogenesis, Activated Astrocytes and Microglia, Remyelination, Molecular Therapies, Adult Neural Stem/Progenitor Cells (NPCs), Adult Mesenchymal Stem Cells (MSCs), Cell Transplantation, Immunemodulation, T and B Cells, Lymph Nodes, Blood Brain Barrier (BBB), Neuroprotection, Regeneration, Therapeutic Plasticity
Current Pharmaceutical Design
Title: Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Volume: 17 Issue: 25
Author(s): Erik Portelius, Niklas Mattsson, Ulf Andreasson, Kaj Blennow and Henrik Zetterberg
Affiliation:
Keywords: Alzheimer's disease, Amyloid, APP, biomarker, theragnostic marker, Abeta-degrading enzymes, Down's syndrome, mass spectrometry, amino acid, Western blot, Subventricular Zone (SVZ) Derived Oligodendrogenesis, Activated Astrocytes and Microglia, Remyelination, Molecular Therapies, Adult Neural Stem/Progenitor Cells (NPCs), Adult Mesenchymal Stem Cells (MSCs), Cell Transplantation, Immunemodulation, T and B Cells, Lymph Nodes, Blood Brain Barrier (BBB), Neuroprotection, Regeneration, Therapeutic Plasticity
Abstract: The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) in the progress of the neurodegenerative disorder Alzheimer´s disease (AD) and it is now widely accepted that Aβ is related to the pathogenesis of AD. For example, studies have shown that Aβ is neurotoxic and that the neurotoxicity of Aβ is related to its aggregation state. The concentration of the 42 amino acid form of Aβ (Aβ1-42) is reduced in the cerebrospinal fluid (CSF) from AD patients, which is believed to reflect the AD pathology with plaques in the brain acting as sinks. Less well investigated, however, is the ability of other Aβ isoforms to distinguish AD patients from controls and to identify treatment effects in clinical trials. Recently, novel C-truncated forms of Aβ (Aβ1-14, Aβ1-15, and Aβ1-16) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by β- followed by α-secretase. It has been shown that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged. Here, we review the many aspects of Aβ and its isoforms with special focus on their potential role as diagnostic and theragnostic markers.
Export Options
About this article
Cite this article as:
Portelius Erik, Mattsson Niklas, Andreasson Ulf, Blennow Kaj and Zetterberg Henrik, Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment, Current Pharmaceutical Design 2011; 17 (25) . https://dx.doi.org/10.2174/138161211797416039
DOI https://dx.doi.org/10.2174/138161211797416039 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Central Nervous System Agents in Medicinal Chemistry Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Survival Signaling Pathways Activated by NMDA Receptors
Current Topics in Medicinal Chemistry Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry Mechano-Regulation of Alternative Splicing
Current Genomics Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents
Current Pharmaceutical Design